Quick Answer
Aspire Biopharma Holdings, Inc. reported Stockholders Equity of -$6.38 million for fiscal year 2025.
Aspire Biopharma Holdings, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$6.38M | -314.0% |
| 2024 | -$1.54M | -215.7% |
| 2023 | -$487.9K | +95.1% |
| 2022 | -$9.94M | -2092089.7% |
| 2021 | -$475.00 | — |
| 2021 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.47M | -1380.8% | -19.2% |
| June 30, 2025 | -$9.62M | -1623.1% | -20.9% |
| March 31, 2025 | -$7.95M | -1523.8% | -416.4% |
| December 31, 2024 | -$1.54M | -215.7% | -98.9% |
| September 30, 2024 | -$774.4K | -1130.1% | -38.8% |
| June 30, 2024 | -$558.1K | -313.2% | -14.0% |
| March 31, 2024 | -$489.7K | +95.2% | -0.4% |
| December 31, 2023 | -$487.9K | +95.1% | -674.9% |
- Aspire Biopharma Holdings, Inc. showed a decrease of -314.0% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Aspire Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: